1. Incremental Prognostic Value of Changes in B-Type Natriuretic Peptide in Heart Failure 
Roberto Latini, MD, Serge Masson, PhD, Maylene Wong, MD, Simona Barlera, MS, Elisa Carretta, MS, Lidia Staszewsky, MD, Tarciso Vago, BiolD, Aldo P. Maggioni, MD, Inder S. Anand, MD, Lip B. Tan, MD, Gianni Tognoni, MD, Jay N. Cohn, MD 
The American Journal of Medicine 
Volume 119, Issue 1, Pages 70.e23-70.e30 (January 2006)
DOI: /j.amjmed
Copyright © 2006 Elsevier Inc. Terms and Conditions

2. Figure 1
Plasma levels of B-type natriuretic peptide in Val-HeFT patients grouped according to changes of B-type natriuretic peptide over time. The number of patients (left) and subsequent 23-month outcome (right) of all-cause mortality (upper panels) and mortality and morbidity (lower panels) are presented for the four categories of B-type natriuretic peptide changes, from baseline to 4 months or baseline to 12 months. BNP = B-type natriuretic peptide; M&M = mortality and morbidity.
The American Journal of Medicine  , 70.e23-70.e30DOI: ( /j.amjmed )
Copyright © 2006 Elsevier Inc. Terms and Conditions

3. Figure 2
Changes in left ventricle ejection fraction (LVEF) and left ventricle internal diameter in diastole adjusted for body surface area (LVIDd/BSA) by the 4 groups of changes in B-type natriuretic peptide from baseline to 4 or 12 months. Changes are expressed as least square means (95% confidence limits), adjusted for their respective baseline value and randomized treatment. Differences between groups were compared by Dunnett-Hsu test, with low→low as reference group, *P <.0001.
The American Journal of Medicine  , 70.e23-70.e30DOI: ( /j.amjmed )
Copyright © 2006 Elsevier Inc. Terms and Conditions